The 6 analysts offering 12-month price forecasts for ProQR Therapeutics NV have a median target of 1.23, with a high estimate of 3.94 and a low estimate of 0.78. The median estimate represents a +50.78% increase from the last price of 0.82.
The current consensus among 8 polled investment analysts is to Hold stock in ProQR Therapeutics NV. This rating has held steady since August, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.21
Reporting Date Nov 21
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.